BRPI1015176A2 - métodos aperfeiçoados para purificação de vetores aav recombinantes - Google Patents

métodos aperfeiçoados para purificação de vetores aav recombinantes

Info

Publication number
BRPI1015176A2
BRPI1015176A2 BRPI1015176A BRPI1015176A BRPI1015176A2 BR PI1015176 A2 BRPI1015176 A2 BR PI1015176A2 BR PI1015176 A BRPI1015176 A BR PI1015176A BR PI1015176 A BRPI1015176 A BR PI1015176A BR PI1015176 A2 BRPI1015176 A2 BR PI1015176A2
Authority
BR
Brazil
Prior art keywords
purification
improved methods
aav vectors
recombinant aav
recombinant
Prior art date
Application number
BRPI1015176A
Other languages
English (en)
Inventor
A Thorne Barbara
Nichols Gina
Mclean Quigley Sheldon Paulene
S Gagnon Peter
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BRPI1015176A2 publication Critical patent/BRPI1015176A2/pt
Publication of BRPI1015176B1 publication Critical patent/BRPI1015176B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicinal Preparation (AREA)
BRPI1015176-1A 2009-06-16 2010-06-16 método para isolar uma população de partículas de vírus adenoassociado recombinante (raav) de impurezas de processo em uma corrente de alimentação BRPI1015176B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18760109P 2009-06-16 2009-06-16
PCT/US2010/038897 WO2010148143A1 (en) 2009-06-16 2010-06-16 Improved methods for purification of recombinant aav vectors

Publications (2)

Publication Number Publication Date
BRPI1015176A2 true BRPI1015176A2 (pt) 2017-09-26
BRPI1015176B1 BRPI1015176B1 (pt) 2019-10-29

Family

ID=43356746

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1015176-1A BRPI1015176B1 (pt) 2009-06-16 2010-06-16 método para isolar uma população de partículas de vírus adenoassociado recombinante (raav) de impurezas de processo em uma corrente de alimentação

Country Status (24)

Country Link
US (4) US10017746B2 (pt)
EP (4) EP3444335B1 (pt)
JP (3) JP5956331B2 (pt)
KR (2) KR101812813B1 (pt)
CN (2) CN105861454B (pt)
BR (1) BRPI1015176B1 (pt)
CA (2) CA2764176C (pt)
CY (3) CY1117936T1 (pt)
DK (2) DK3444335T3 (pt)
ES (3) ES2693194T3 (pt)
HK (1) HK1165830A1 (pt)
HR (2) HRP20181743T1 (pt)
HU (3) HUE054940T2 (pt)
IL (3) IL216960A (pt)
LT (2) LT3444335T (pt)
MX (2) MX2011013613A (pt)
PL (2) PL3067417T3 (pt)
PT (3) PT2443233T (pt)
RS (2) RS57784B1 (pt)
RU (1) RU2016119739A (pt)
SG (2) SG176283A1 (pt)
SI (2) SI3444335T1 (pt)
TR (1) TR201815937T4 (pt)
WO (1) WO2010148143A1 (pt)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9198984B2 (en) 2006-04-28 2015-12-01 The Trustees Of The University Of Pennsylvania Scalable production method for AAV
SG176283A1 (en) * 2009-06-16 2012-01-30 Genzyme Corp Improved methods for purification of recombinant aav vectors
CA2787009C (en) 2010-01-15 2018-04-03 Bio-Rad Laboratories, Inc. Surface neutralization of apatite
US8895707B2 (en) 2010-08-18 2014-11-25 Bio-Rad Laboratories, Inc. Elution of proteins from hydroxyapatite resins without resin deterioration
US9592540B2 (en) 2011-02-02 2017-03-14 Bio-Rad Laboratories, Inc. Apatite surface neutralization with alkali solutions
WO2012123488A1 (en) 2011-03-16 2012-09-20 F. Hoffmann-La Roche Ag Ion exchange chromatography with improved selectivity for the separation of polypeptide monomers, aggregates and fragments by modulation of the mobile phase
WO2012144446A1 (ja) * 2011-04-18 2012-10-26 独立行政法人国立精神・神経医療研究センター 薬剤送達粒子及びその製造方法
AU2012304993B2 (en) * 2011-09-08 2017-09-14 Uniqure Ip B.V. Removal of contaminating viruses from AAV preparations
US9815695B2 (en) 2012-05-30 2017-11-14 Bio-Rad Laboratories, Inc. In situ restoration of apatite-based chromatography resins
JP6200949B2 (ja) * 2012-05-31 2017-09-20 エイジェンシー フォー サイエンス，テクノロジー アンド リサーチ 固相ウレイドに対する生物学的標的物の選択的結合
EP2956541B1 (en) * 2013-02-15 2018-12-26 Douglas T. Gjerde Devices and methods for purification of biological cells
US11332719B2 (en) 2013-03-15 2022-05-17 The Broad Institute, Inc. Recombinant virus and preparations thereof
WO2014145578A1 (en) * 2013-03-15 2014-09-18 The Children's Hospital Of Philadelphia Scalable manufacturing process to produce recombinant lentiviral vectors in serum-free suspension cell culture system
SG10201708547YA (en) 2013-04-17 2017-11-29 Genzyme Corp Compositions and methods for treating and preventing macular degeneration
CN105339495A (zh) * 2013-07-11 2016-02-17 宝生物工程株式会社 制备无包膜病毒的方法
MX2016010215A (es) 2014-02-06 2016-11-15 Genzyme Corp Composiciones y metodos de tratamiento y prevencion de degeneracion macular.
HUE054768T2 (hu) 2014-05-02 2021-09-28 Genzyme Corp AAV vektorok retina és CNS génterápiára
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
WO2015200282A1 (en) 2014-06-23 2015-12-30 Bio-Rad Laboratories, Inc. Apatite pretreatment
WO2015200299A2 (en) 2014-06-23 2015-12-30 Bio-Rad Laboratories, Inc. Apatite in-situ restoration
WO2016006658A1 (ja) 2014-07-10 2016-01-14 タカラバイオ株式会社 非エンベロープウイルス粒子の製造方法
CN104232687A (zh) * 2014-09-17 2014-12-24 许瑞安 一种重组腺相关病毒rAAV载体的分离纯化方法
TW201628649A (zh) 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
MX2017005834A (es) 2014-11-05 2017-11-17 Voyager Therapeutics Inc Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
RU2749882C2 (ru) 2014-11-14 2021-06-18 Вояджер Терапьютикс, Инк. Модулирующие полинуклеотиды
EP3218484A4 (en) 2014-11-14 2018-05-30 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
CN107109374B (zh) 2015-01-09 2021-04-06 宝生物工程株式会社 用于生产无包膜病毒颗粒的方法
IL310375A (en) 2015-01-20 2024-03-01 Genzyme Corp Analytical ultracentrifugation for characterization of recombinant viral particles
EP3054006A1 (en) * 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography
EP3054007A1 (en) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
HUE057272T2 (hu) 2015-02-10 2022-04-28 Genzyme Corp Vírusrészecskék fokozott bevitele a csíkolt testbe és az agykéregbe
TWI707951B (zh) 2015-04-08 2020-10-21 美商健臻公司 過大腺相關載體之製造
CN105907729B (zh) * 2015-05-05 2019-08-16 广东东阳光药业有限公司 一种制备人乳头瘤病毒l1蛋白类病毒样颗粒的方法
US20170067028A1 (en) * 2015-05-15 2017-03-09 Douglas J. Ballon Radiolabeling of adeno associated virus
CN107849547B (zh) 2015-05-16 2022-04-19 建新公司 深内含子突变的基因编辑
US9663766B2 (en) 2015-07-24 2017-05-30 Bio-Rad Laboratories, Inc. Methods for purifying adenovirus vectors
US11015173B2 (en) 2015-12-11 2021-05-25 The Trustees Of The University Of Pennsylvania Scalable purification method for AAV1
US11098286B2 (en) 2015-12-11 2021-08-24 The Trustees Of The University Of Pennsylvania Scalable purification method for AAV9
WO2017100704A1 (en) 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Scalable purification method for aavrh10
ES2934848T3 (es) 2015-12-11 2023-02-27 Univ Pennsylvania Método de purificación escalable para AAV8
SG11201804994QA (en) 2015-12-15 2018-07-30 Genzyme Corp Adeno-associated viral vectors for treating mucolipidosis type ii
US11208630B2 (en) 2015-12-24 2021-12-28 University Of Florida Research Foundation, Incorporated AAV production using suspension adapted cells
HUE061100T2 (hu) 2016-03-28 2023-05-28 Ultragenyx Pharmaceutical Inc Adenovírus hõinaktiválásának módszerei
BR112018070256A2 (pt) * 2016-03-31 2019-01-29 Spark Therapeutics Inc processo de fabricação de raav totalmente escalável à base de colunas
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
GB201608046D0 (en) 2016-05-09 2016-06-22 Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The Treatment of complement-mediated disorders
RU2758488C2 (ru) 2016-05-18 2021-10-28 Вояджер Терапьютикс, Инк. Модулирующие полинуклеотиды
JP7220080B2 (ja) 2016-05-18 2023-02-09 ボイジャー セラピューティクス インコーポレイテッド ハンチントン病治療組成物及び方法
GB201612248D0 (en) * 2016-07-14 2016-08-31 Puridify Ltd New process
CN118688363A (zh) 2016-08-15 2024-09-24 建新公司 检测aav的方法
IL264631B2 (en) 2016-08-16 2024-05-01 Regeneron Pharma A method for quantifying individual antibodies from a mixture
CN110225975A (zh) 2016-08-23 2019-09-10 阿库斯股份有限公司 用于治疗人受试者中非年龄相关的听力损害的组合物和方法
EP3506817A4 (en) 2016-08-30 2020-07-22 The Regents of The University of California METHOD FOR BIOMEDICAL TARGETING AND RELEASE, AND DEVICES AND SYSTEMS FOR IMPLEMENTING THEM
EP3526321A4 (en) 2016-10-14 2020-05-13 Ultragenyx Pharmaceutical Inc. USE OF TONIFYING AGENTS TO IMPROVE THE YIELD OF RECOMBINANT ADENO-ASSOCIATED VIRUS
SG11201902667UA (en) 2016-10-25 2019-05-30 Regeneron Pharma Methods and systems for chromatography data analysis
SG11201903890QA (en) * 2016-11-04 2019-05-30 Baxalta Inc Adeno-associated virus purification methods
US10626376B2 (en) * 2016-11-14 2020-04-21 St. Jude Children's Research Hospital Method for isolating and purifying adeno-associated virus particles using salt
JP7142643B2 (ja) 2017-03-22 2022-09-27 ウルトラジェニックス ファーマシューティカル インコーポレイテッド Ｈｄａｃ阻害剤またはｒｅｐタンパク質を伴う細胞培養方法
WO2018204803A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
WO2018204786A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
KR102669561B1 (ko) * 2017-06-30 2024-05-24 스파크 테라퓨틱스, 인코포레이티드 Aav 벡터 컬럼 정제 방법
JP7229989B2 (ja) 2017-07-17 2023-02-28 ボイジャー セラピューティクス インコーポレイテッド 軌道アレイガイドシステム
EP3662060A2 (en) 2017-08-03 2020-06-10 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
SG11202001564QA (en) 2017-09-19 2020-04-29 Regeneron Pharma Methods of reducing particle formation and compositions formed thereby
EP3697908A1 (en) 2017-10-16 2020-08-26 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
EP4124658A3 (en) 2017-10-16 2023-04-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
MA50942A (fr) 2017-12-01 2020-10-07 Encoded Therapeutics Inc Protéines de liaison à l'adn modifiées
AU2018395254B2 (en) 2017-12-29 2024-07-25 Takeda Pharmaceutical Company Limited Adeno-associated virus purification methods
US10610606B2 (en) 2018-02-01 2020-04-07 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
EP3755795A4 (en) 2018-02-19 2022-07-20 Homology Medicines, Inc. ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR RECOVERING F8 GENE FUNCTION AND METHODS OF USE THEREOF
EP3787771A1 (en) * 2018-04-29 2021-03-10 REGENXBIO Inc. Scalable clarification process for recombinant aav production
US11884698B2 (en) 2018-07-02 2024-01-30 Regeneron Pharmaceuticals, Inc. Systems and methods for preparing a polypeptide from a mixture
US20210355454A1 (en) * 2018-07-24 2021-11-18 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations
JP7070238B2 (ja) * 2018-08-22 2022-05-18 株式会社島津製作所 液体クロマトグラフ分析装置、移動相供給装置、液体クロマトグラフ分析方法および移動相供給方法
EA202190512A1 (ru) * 2018-09-21 2021-11-17 Найтстаркс Лимитед Композиции и способы для производства векторов для генной терапии
US20210348135A1 (en) 2018-10-12 2021-11-11 Genzyme Corporation Generation of improved human pah for treatment of severe pku by liver-directed gene replacement therapy
TW202039854A (zh) 2018-11-16 2020-11-01 美商編碼製藥公司 治療威爾遜氏病的組合物和方法
CA3136872A1 (en) 2019-04-23 2020-10-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) New adeno-associated virus (aav) variants and uses thereof for gene therapy
US10653731B1 (en) 2019-07-15 2020-05-19 Vigene Biosciences Inc. Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
US10801042B1 (en) 2019-07-15 2020-10-13 Vigene Biosciences, Inc. Use of ion concentrations to increase the packaging efficiency of recombinant adeno-associated virus
US10557149B1 (en) 2019-07-15 2020-02-11 Vigene Biosciences, Inc. Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus
TW202140791A (zh) 2020-01-13 2021-11-01 美商霍蒙拉奇醫藥公司 治療苯酮尿症之方法
CN115989234A (zh) 2020-01-29 2023-04-18 建新公司 用于眼部基因疗法的经修饰的腺相关病毒衣壳蛋白及其使用方法
AU2021225035A1 (en) 2020-02-21 2022-10-13 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
TW202208632A (zh) 2020-05-27 2022-03-01 美商同源醫藥公司 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
EP3919613B1 (en) * 2020-06-05 2024-08-07 Sartorius BIA Separations d.o.o. Enhanced purification of adeno-associated virus to more effectively remove contaminating dna
JP6898535B1 (ja) * 2020-06-16 2021-07-07 ＨＯＹＡ Ｔｅｃｈｎｏｓｕｒｇｉｃａｌ株式会社 アパタイトカラムを使用したウイルスの精製方法
CN111808828B (zh) * 2020-09-14 2020-11-17 和元生物技术（上海）股份有限公司 腺相关病毒的分离纯化方法
KR20230079172A (ko) 2020-10-01 2023-06-05 젠자임 코포레이션 간-유도 유전자 대체 요법에 의한 pku의 치료를 위한 인간 pah 발현 카세트
KR20230154039A (ko) 2021-03-09 2023-11-07 제이씨알 파마 가부시키가이샤 재조합 aav9 비리온의 제조 방법
US20240159718A1 (en) 2021-03-22 2024-05-16 Genzyme Corporation Size exclusion chromatography analysis of empty and full aav capsids
TW202400250A (zh) 2022-04-12 2024-01-01 美商健臻公司 Irak4調節劑於基因療法之用途(一)
TW202402329A (zh) 2022-04-12 2024-01-16 美商健臻公司 Irak4調節劑於基因療法之用途(二)
US20230407255A1 (en) 2022-04-12 2023-12-21 Genzyme Corporation Dendritic cell assay for innate immunogenicity to gene therapy agents
US20230346977A1 (en) 2022-04-13 2023-11-02 Universitat Autònoma De Barcelona Treatment of neuromuscular diseases via gene therapy that expresses klotho protein
TW202403049A (zh) 2022-05-16 2024-01-16 美商健臻公司 治療異染性白質失養症之方法
WO2023240062A1 (en) 2022-06-07 2023-12-14 Adverum Biotechnologies, Inc. Melanopsin variants for vision restoration

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008298A1 (en) * 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
DK1944362T3 (en) 1997-09-05 2016-01-25 Genzyme Corp Fremgangsmåder til fremstilling af hjælpevirusfri præparater med høj titer af rekombinante AAV-vektorer
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
US7419817B2 (en) 2002-05-17 2008-09-02 The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
US20090047723A1 (en) * 2005-01-14 2009-02-19 Bayer Healthcare Llc Method for purification of factor vii
KR20150098681A (ko) * 2007-03-14 2015-08-28 다케다 백신즈 인코포레이티드 바이러스 유사 입자 정제
GB2467320A (en) 2009-01-28 2010-08-04 Surrey Nanosystems Ltd Two methods of forming carbon nano-materials using filtered acetylene gas
SG176283A1 (en) * 2009-06-16 2012-01-30 Genzyme Corp Improved methods for purification of recombinant aav vectors

Also Published As

Publication number Publication date
BRPI1015176B1 (pt) 2019-10-29
CN105861454A (zh) 2016-08-17
PL2443233T3 (pl) 2017-08-31
MX352986B (es) 2017-12-15
CN102803478B (zh) 2016-04-27
EP3067417A2 (en) 2016-09-14
HK1165830A1 (zh) 2012-10-12
CA2764176C (en) 2020-06-02
ES2693194T3 (es) 2018-12-10
IL253205A0 (en) 2017-08-31
TR201815937T4 (tr) 2018-11-21
RS57784B1 (sr) 2018-12-31
HUE054940T2 (hu) 2021-10-28
IL216960A0 (en) 2012-02-29
MX2011013613A (es) 2012-01-19
ES2588990T3 (es) 2016-11-08
SG176283A1 (en) 2012-01-30
CN102803478A (zh) 2012-11-28
EP3067417A3 (en) 2016-11-02
WO2010148143A1 (en) 2010-12-23
HRP20181743T1 (hr) 2019-02-22
SI3444335T1 (sl) 2021-08-31
LT3067417T (lt) 2018-11-12
CY1117936T1 (el) 2017-05-17
PL3067417T3 (pl) 2019-02-28
KR20120047213A (ko) 2012-05-11
JP2019083822A (ja) 2019-06-06
RS62086B1 (sr) 2021-08-31
US20190010468A1 (en) 2019-01-10
JP2012529917A (ja) 2012-11-29
DK3444335T3 (da) 2021-07-26
CA3077531A1 (en) 2010-12-23
KR20180000341A (ko) 2018-01-02
IL253205B (en) 2018-07-31
EP2443233A4 (en) 2013-05-29
SG10201403290SA (en) 2014-10-30
US20210139860A1 (en) 2021-05-13
US20240287467A1 (en) 2024-08-29
EP3444335A1 (en) 2019-02-20
CY1121442T1 (el) 2020-05-29
JP2016195600A (ja) 2016-11-24
PT3444335T (pt) 2021-07-12
CA3077531C (en) 2022-09-20
EP3067417B1 (en) 2018-07-25
JP6788056B2 (ja) 2020-11-18
CA2764176A1 (en) 2010-12-23
RU2016119739A (ru) 2018-11-05
EP3919614A1 (en) 2021-12-08
DK3067417T3 (en) 2018-11-19
ES2881050T3 (es) 2021-11-26
US10017746B2 (en) 2018-07-10
CY1124323T1 (el) 2022-07-22
HUE040636T2 (hu) 2019-03-28
IL216960A (en) 2017-07-31
RU2012101475A (ru) 2013-07-27
PT2443233T (pt) 2016-08-17
IL260215A (en) 2018-07-31
EP3444335B1 (en) 2021-04-14
EP2443233A1 (en) 2012-04-25
KR101812813B1 (ko) 2017-12-27
PT3067417T (pt) 2018-11-13
US20150024467A1 (en) 2015-01-22
JP6496684B2 (ja) 2019-04-03
HRP20211120T1 (hr) 2021-10-15
EP2443233B1 (en) 2016-06-01
CN105861454B (zh) 2020-03-03
US11840710B2 (en) 2023-12-12
LT3444335T (lt) 2021-07-26
US10696952B2 (en) 2020-06-30
HUE028341T2 (en) 2016-12-28
JP5956331B2 (ja) 2016-07-27
SI3067417T1 (sl) 2018-11-30

Similar Documents

Publication Publication Date Title
BRPI1015176A2 (pt) métodos aperfeiçoados para purificação de vetores aav recombinantes
BR112013008738A2 (pt) processos para purificação de proteínas
HK1246330A1 (zh) 蛋白質純化
IL221158B (en) Methods for vector purification of the aav virus
DK2677753T3 (da) Fremgangsmåde til at afkode bevægelsesvektorer
DK2691411T3 (da) Buffersystem til proteinoprensning
PL2307551T3 (pl) Oczyszczanie wektorów retrowirusowych
BR112013024521A2 (pt) métodos de purificação de proteínas
ES2547827T8 (es) Procedimiento para la purificación de la micafungina
EP2519537A4 (en) CLEANING PROTEINS
BRPI0922812A2 (pt) antígeno recombinante para detecção de toxocaríase
IT1398690B1 (it) Interruttore per veicoli
ES1075075Y (es) Collarin para losa de tumba o panteon
TH1201005165B (th) การทำให้บริสุทธิ์ของโพรพิลีนออกไซด์ (Propylene oxide)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/06/2010, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/06/2010, OBSERVADAS AS CONDICOES LEGAIS